Navigation Links
ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
Date:2/4/2011

CAMBRIDGE, Mass.,  Feb. 4, 2011 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced today it has elected Anil Godhwani, a successful Silicon Valley entrepreneur, to its board of directors. ALS TDI is a 501(c)(3) "nonprofit biotechnology" organization with a mission to discover and develop treatments that effectively slow and stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease).

(Logo: http://photos.prnewswire.com/prnh/20110204/DC42625LOGO)

"My mother was diagnosed with ALS last year and the disease is progressing rapidly. Shortly after her diagnosis, we met the amazing ALS TDI staff and their dedicated chairman Augie Nieto. I am honored to join the Board and work with my fellow directors to ensure that the Institute has the support it needs to continue to find ways to reduce the time and cost of drug development. I have no doubt that this organization will continue to change the way the world thinks about ALS," said Godhwani.

Godhwani is the co-founder of Simply Hired, an online job search engine based in Mountain View, Calif. The site has over 14 million visitors per month. Prior to Simply Hired Godhwani founded AtWeb, an online promotion and maintenance company, which he sold in 1998. Godhwani is also the co-founder of the India Community Center (ICC) in Milpitas, Calif., the largest Indo-American focused community organization in the country providing hundreds of programs annually to community members. Godhwani has helped raise over $15 million for ICC.

"Each member of our Board plays a unique role in helping us achieve our mission. As a successful entrepreneur and community philanthropist Anil will bring new experiences and fresh ideas. The executive team is looking forward to working with him, and the entire ALS community will benefit from having him take on a leadership role at ALS TDI," said the Institute's CEO & CSO, Dr. Steve Perrin.

Mr. Godhwani becomes the 12th member of the Board of Directors at ALS TDI. For information on the rest of the board, please visit http://www.als.net.  

About the ALS Therapy Development Institute

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), as soon as possible.  Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, and operates the world's largest effort to pre-clinically validate potential therapeutics.  The world's first nonprofit biotech, ALS TDI has developed an industrial-scale platform that allows for the development and testing of dozens of potential therapeutics each year. Built by and for patients, the Institute is the world's only nonprofit biotechnology company with more than 30 professional scientists.  In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry to accelerate ALS therapeutic development.  For more information, please visit us online at www.als.net.

Media Contact: Robert A. Goldstein, ALS TDI, rgoldstein@als.net, 617-441-7295


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy
2. Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
3. NewLink Genetics to Present Phase 2 Data of Its HyperAcute® Pancreas Immunotherapy at ASCO 2011 Gastrointestinal Cancers Symposium
4. NeoStem Acquires Progenitor Cell Therapy
5. Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy
6. HRC Medical Center Offers Patients Relief with Innovative Bio-Identical Hormone Replacement Therapy
7. Reportlinker Adds Gene Therapy - technologies, markets and companies
8. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
9. Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System
10. Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
11. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... MANHASSET, N.Y. , Jan. 16, 2017   ... Kevin J. Tracey, MD , president and CEO of ... Northwell Health, completed an analysis of how the nervous ... further identify and develop bioelectronic medicine devices ... today in Nature Neuroscience . The ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/14/2017)... , Jan. 13, 2017  The Alliance for Safe ... response to FDA final guidance on biologic ... continued leadership in emphasizing the importance of distinct naming ... aware of the benefits biosimilars will bring to patients, ... Yet the portion of the Guidance dealing with ...
(Date:1/13/2017)... , Jan 13, 2017 Research and Markets has ... to their offering. ... global biopolymers market to grow at a CAGR of 16.83% during the ... the growth prospects of the global biopolymers market for 2017-2021. To calculate ... of sales of biopolymer products. The report also includes a a discussion ...
Breaking Biology Technology:
(Date:12/22/2016)...  As part of its longstanding mission to improve genetic ... recently released its latest children,s book, titled The ... the topics of inheritance and variation of traits that are ... elementary school classrooms in the US. The ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/20/2016)... The rising popularity of mobility services ... stoking significant interest in keyless access systems. Following ... energy (BLE), biometrics and near-field communication (NFC) are ... wireless technologies in the automotive industry. This evolution ... systems opens the market to specialist companies such ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
Breaking Biology News(10 mins):